Amneal published its Q1 2022 financial results, reporting a 1% increase YoY in net revenue. Amneal announced that it plans to expand into high growth areas including biosimilars and injectables.
Zoetis Vaccine Patents’ Last Stand
Boehringer Ingelheim Animal Health USA Inc v Zoetis Services LLC (No 2) [2024] FCA 291 Date:Court:Adjudicator: 26 March 2024Federal...